Nuclear Localization of KLF4 Is Associated with An Aggressive Phenotype in Early-Stage Breast Cancer

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2709-2719

  Pandya, Ashka Y ^a   Talley, Lynya I ^b   Frost, Andra R ^c   Fitzgerald, Thomas J ^b   Trivedi, Vivek ^b   Chakravarthy, Mithun ^c   Chhieng, David C ^c   Grizzle, William E ^c   Engler, Jeffrey A ^e   Krontiras, Helen ^d   Bland, Kirby I ^d   LoBuglio, Albert F ^b   Lobo Ruppert, Susan M ^b   Ruppert, J Michael ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d Kentucky   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; KRUPPEL LIKE FACTOR; PROTEIN BCL 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSOCIATION; BREAST CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CELLULAR DISTRIBUTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; EMBRYO; EPITHELIUM CELL; HAZARD; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MULTIVARIATE ANALYSIS; NUCLEAR LOCALIZATION SIGNAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STAINING;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CYTOPLASM; CYTOSOL; DISEASE-FREE SURVIVAL; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; EPITOPES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MULTIVARIATE ANALYSIS; PHENOTYPE; PLASMIDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; REGRESSION ANALYSIS; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; TREATMENT OUTCOME; UP-REGULATION;

EID: 11144358328     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0484     Document Type: Article

References (44)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Taipale J, Beachy PA. The Hedgehog and Wnt signaling pathways in cancer. Nature (Lond.) 2001;411:349-54.
3. Tetsu O, Mccormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (Lond.) 1999;398:422-6.
4. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science (Wash. DC) 1998;281:1509-12.
5. Kogerman P, Grimm T, Kogerman L, et al. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. Nat Cell Biol 1999;1:312-9.
6. Murone M, Luoh SM, Stone D, et al. Gli regulation by the opposing activities of fused and suppressor of fused. Nat Cell Biol 2000;2:310-2.
7. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31:306-10.
8. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a β-catenin-TCF complex in APC-/- colon carcinoma. Science (Wash. DC) 1997;275:1784-7.
9. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-TCF signaling in colon cancer by mutations in β-catenin or APC. Science (Wash. DC) 1997;275:1787-90.
10. Kolligs FT, Kolligs B, Hajra KM, et al. γ-Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of β-catenin. Genes Dev 2000;14:1319-31.
11. Foster KW, Ren S, Louro ID, et al. Oncogene expression cloning by retroviral transduction of adenovirus Ela-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. Cell Growth Differ 1999;10:423-34.
12. Foster KW, Frost AR, McKie-Bell P, et al. Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res 2000;60:6488-95.
13. Segre JA, Bauer C, Fuchs E. Klf4 is a transcription factor required for establishing the barrier function of the skin. Nat Genet 1999;22:356-60.
14. Garrett-Sinha LA, Eberspaecher H, Seldin MF, de Crombrugghe B. A gene for a novel zinc-finger protein expressed in differentiated epithelial cells and transiently in certain mesenchymal cells. J Biol Chem 1996;271:31384-90.
15. Shields JM, Christy RJ, Yang VW. Identification and characterization of a gene encoding a gut-enriched Krüppel-like factor expressed during growth arrest. J Biol Chem 1996;271:20009-17.
16. Chen ZY, Shie JL, Tseng CC. Gut-enriched Kruppel-like factor represses ornithine decarboxylase gene expression and functions as checkpoint regulator in colonic cancer cells. J Biol Chem 2002;277:46831-9.
17. Shie JL, Chen ZY, Fu M, Pestell RG, Tseng CC. Gut-enriched Kruppel-like factor represses cyclin D1 promoter activity through Spl motif. Nucleic Acids Res 2000;28:2969-76.
18. Zhang W, Geiman DE, Shields JM, et al. The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J Biol Chem 2000;275:18391-8.
19. Shields JM, Yang VW. Identification of the DNA sequence that interacts with the gut-enriched Krüppel-like factor. Nucleic Acids Res 1998;26:796-802.
20. Shields JM, Yang VW. Two potent nuclear localization signals in the gut-enriched Krüppel-like factor define a subfamily of closely related Krüppel proteins. J Biol Chem 1997;272:18504-7.
21. Pandya K, Townes TM. Basic residues within the Kruppel zinc finger DNA binding domains are the critical nuclear localization determinants of EKLF/KLF-1. J Biol Chem 2002;277:16304-12.
22. Quadrini KJ, Bieker JJ. Kruppel-like zinc fingers bind to nuclear import proteins and are required for efficient nuclear localization of erythroid Kruppel-like factor. J Biol Chem 2002;277:32243-52.
23. King KE, Iyemere VP, Weissberg PL, Shanahan CM. Kruppel-like factor 4 (KLF4/GKLF) is a target of bone morphogenetic proteins and transforming growth factor β1 in the regulation of vascular smooth muscle cell phenotype. J Biol Chem 2003;278:11661-9.
24. Greene FL, Page DL, Fleming ID, et al. (editors). Breast. In: AJCC cancer staging manual, New York: Springer-Verlag;2002. p. 223-40.
25. Frost AR, Sparks D, Grizzle WE. Methods of antigen recovery vary in their usefulness in unmasking specific antigens in immunohistochemistry. Appl Immunohistochem Mol Morphol 2000;8:236-43.
26. Grizzle WE, Myers RB, Manne U, Srivastava S. Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. In: Hanausek M, Walaszek Z (editors). Methods in molecular medicine: tumor marker protocols. Totowa, NJ: Humana Press, Inc.; 1998. p. 143-60.
27. Grizzle WE, Myers RB, Manne U, Stockard CR, Harkin LE, Srivastava S. Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia. In: Hanausek M, Walaszek Z (editors). Methods in molecular medicine: tumor marker protocols. Totowa, NJ: Humana Press, Inc.;1998. p. 161-79.
28. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
29. Fisher RA. The logic of inductive inference. J R Stat Soc [A] 1935;98:39-54.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
31. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
32. Jarvik JW, Telmer CA. Epitope tagging. Annu Rev Genet 1998;32:601-18.
33. Ruppert JM, Vogelstein B, Kinzler KW. The zinc finger protein GLI transforms rodent cells in cooperation with adenovirus E1A. Mol Cell Biol 1991;11:1724-8.
34. Hutter RVP, Kennedy BJ, Murphy GP, O'Sullivan B, Sobin LH, Yarbro JW (editors). Breast. AJCC cancer staging manual, Philadelphia: Lippincott-Raven;1998. p. 171-80.
35. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N. Engl J Med 2002;347:1566-75.
36. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (editors), Diseases of the breast. Philadelphia: Lippincott Williams & Wilkins;2000. p. 489-514.
37. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst (Bethesda) 1994;86:499-504.
38. Turner BC, Krajewski S, Krajewska M, et al. BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol 2001;19:992-1000.
39. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the Ed. 6 of the AJCC cancer staging manual. Surg Clin N Am 2003;83:803-19.
40. Geiman DE, Han TT, Johnson JM, Yang VW. Transactivation and growth suppression by the gut-enriched Krüppel-like factor (Krüppel-like factor 4) are dependent on acidic amino acid residues and protein-protein interaction. Nucleic Acids Res 2000;28:1106-13.
41. Adam PJ, Regan CP, Hautmann MB, Owens GK. Positive- and negative-acting Kruppel-like transcription factors bind a transforming growth factor β control element required for expression of the smooth muscle cell differentiation marker SM22α in vivo. J Biol Chem 2000;275:37798-806.
42. Beenken SW, Bland KI. Biomarkers for breast cancer. Minerva Chir 2002;57:437-48.
43. Morabito A, Magnani E, Gion M, et al. Prognostic and predictive indicators in operable breast cancer. Clin Breast Cancer 2003;3:381-90.
44. Klijn JGM, Berns EMJJ, Foekens JA. Prognostic and predictive factors and targets for therapy in breast cancer. In: Pasqualini JR (editor). Breast cancer: prognosis, treatment, and prevention. New York: Marcel Dekker, Inc.;2002. p. 93-124.